Marie Sofie Reinert

Marie Sofie Reinert

Auto-generated profile, based on publicly available information

Marie Sofie Reinert

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, Copenhagen 2100

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Circulation
Verified
Journal Article
Closed access
MRMarie Sofie Reinert
Marie Sofie Reinert
HRHelene Vistisen Ryde
Helene Vistisen Ryde
LSLouise Marqvard Sørensen
Louise Marqvard Sørensen
SJSofie Engstrøm Johansen
Sofie Engstrøm Johansen
PSPernille Fog Svendsen
Pernille Fog Svendsen
EHEva Havers-Borgersen
Eva Havers-Borgersen
BACKGROUND: Polycystic ovarian syndrome (PCOS) is associated with increased cardiovascular morbidity and a higher risk of atherosclerotic cardiovascular disease. PCOS has been associated with electrocardiographic alterations. However, the potential long-term risk of cardiac arrhythmias in women with PCOS remains insufficiently investigated. METHODS: Women diagnosed with PCOS in Denmark (1977–2024) were matched on age and year of index with female controls from the background population (ratio 1:4). The primary outcome was incident arrhythmia, with subtype of arrhythmia and cardiac implantable electronic device (CIED, ie, pacemaker and cardioverter defibrillator implantation) implantation as secondary outcomes. Patients were followed from date of PCOS diagnosis until date of event, emigration, death, or end of study (January 31, 2024). RESULTS: The study included 26 728 women with PCOS (median age, 27.8 years [interquartile range, 23.7–32.1]) and 106 912 controls. Women with PCOS had a higher comorbidity burden and pharmacotherapy use compared with controls. The 25-year associated risk of arrhythmias was higher among women with PCOS (6.3% [95% CI, 5.6–6.9]) compared with controls (4.2% [95% CI, 3.9–4.5]), equivalent to incidence rates of 23.8 (95% CI, 22.1–25.6) and 15.7 (95% CI, 15.0–16.4) per 10 000 person-years, respectively, an unadjusted hazard ratio (HR) of 1.56 (95% CI, 1.43–1.71), and an adjusted HR of 1.48 (95% CI, 1.35–1.63). Across subtypes of arrhythmias, women with PCOS were associated with a higher risk of advanced atrioventricular block (adjusted HR, 1.76 [95% CI, 1.05–2.93]), cardiac arrest (adjusted HR, 1.44 [95% CI, 1.03–2.08]), and atrial fibrillation or flutter (adjusted HR, 1.44 [95% CI, 1.20–1.73]) compared with controls. Women with PCOS were more likely to receive a CIED compared with controls (incidence rates of 1.9 [95% CI, 1.5–2.5] and 1.1 [95% CI, 0.9–1.3] per 10 000 person-years, respectively; adjusted HR, 1.85 [95% CI, 1.30–2.63]). The higher associated risk of arrhythmias and likelihood of receiving a CIED among women with PCOS was independent of use of metformin, oral contraception, spironolactone, antiandrogens, and glucagon-like peptide receptor analogs. CONCLUSIONS: Women with PCOS had a higher associated long-term risk of developing arrhythmias and a higher incidence of receiving a CIED compared with female controls from the background population. Despite low absolute event rates, these findings emphasize the clinical relevance of early cardiovascular risk assessment and preventive strategies for patients diagnosed with PCOS.

11 July 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
MRMarie Sofie Reinert
Marie Sofie Reinert
EHEva Havers-Borgersen
Eva Havers-Borgersen
PGPeter Laursen Graversen
Peter Laursen Graversen
HVHelene Vistisen
Helene Vistisen
JSJarl Emanuel Strange
Jarl Emanuel Strange
EFEmil L Fosbøl
Emil L Fosbøl
Aims: Recent advancements in transcatheter aortic valve implantation (TAVI) and patient selection have significantly improved the outcomes of TAVI. Yet it is unknown whether patients undergoing TAVI in the modern era have comparable mortality as the general population. Methods and results: All patients undergoing TAVI in Denmark (2015–23) were matched on age and sex with controls from the general population (1:4). Patients were followed from 30-day post-TAVI until death or end of study (12/23). The 5-year all-cause mortality was examined by cumulative incidence functions and Cox-regression analyses. The 5-year all-cause hospitalization burden was analysed among those alive at 5-year post-index. The study included 7250 patients undergoing TAVI [median age 81.2 years (IQR 77.0–84.9), 57.3% men] and 29 000 controls. The absolute risk of death was 39.6% [95% confidence interval (CI) 38.1–41.2] in the TAVI group, compared to 32.2% (95% CI 31.5–32.9) among controls. The associated all-cause mortality was similar between patients undergoing TAVI and controls [adjusted hazard ratio 0.95 (95% CI 0.90–1.01)]. Stratification by age revealed a higher risk of death among the TAVI group aged <80 years compared with controls, while patients aged ≥80 years showed a lower risk of death. Patients undergoing TAVI experienced longer and more frequent hospitalizations compared with controls, while the relative difference decreased over time. Conclusion: Our findings suggest that TAVI was associated with long-term mortality and hospitalization rates comparable to the general population. Stratified by age, mortality was higher among TAVI patients <80 years and lower among those ≥80 years. These findings support patient selection, safety, and long-term outcomes of TAVI.

8 August 2026 in European Heart Journal
Verified
Journal Article
Closed access
HRHelene Vistisen Ryde
Helene Vistisen Ryde
MRMarie S Reinert
Marie S Reinert
DHDorthe Hartwell
Dorthe Hartwell
CECharlotte Ekelund
Charlotte Ekelund
LKLars Valeur Köber
Lars Valeur Köber
EHEva Havers-Borgersen
Eva Havers-Borgersen
Background and Aims: Endometriosis affects ∼10% of women of reproductive age. Emerging evidence suggests a link between endometriosis and systemic inflammation, potentially increasing the risk of venous thromboembolism (VTE), yet data on the association between endometriosis and VTE are lacking. The aim was to examine the association between endometriosis and long-term risk of VTE. Methods: A nationwide, registry-based cohort study including all women with endometriosis from 1977 to 2024, matched 1:4 on birth and index year with women from the background population without endometriosis. The primary outcome was VTE as a composite of deep venous thrombosis and pulmonary embolism, while the individual components comprised the secondary outcomes. Results: The study included 63 999 women with endometriosis and 255 996 matched female controls. At baseline, women with endometriosis had a higher burden of comorbidities, had greater use of medications, and more often had a history of abdominal/gynaecological surgeries. The incidence rate of VTE was higher in women with endometriosis [2.18 per 1000 person-years; 95% confidence interval (CI) 2.10–2.26] compared with controls (1.54 per 1000 person-years; 95% CI 1.51–1.58). In Cox regression analyses, endometriosis was associated with a significantly increased risk of VTE, even after adjustment for relevant comorbidities and use of hormonal contraception [unadjusted hazard ratio (HR) 1.43; 95% CI 1.36–1.50 and adjusted HR 1.52; 95% CI 1.42–1.63]. Similar results were observed for VTE subgroups: deep venous thrombosis alone (adjusted HR 1.50; 95% CI 1.38–1.63) and pulmonary embolism alone (adjusted HR 1.52; 95% CI 1.36–1.70). Conclusions: Endometriosis was associated with an increased long-term risk of VTE compared with a matched background population. These findings highlight the importance of clinical awareness and consideration of thrombotic risk in women with a history of endometriosis.